How to buy Eyepoint Pharmaceuticals stock (EYPT)

Eyepoint Pharmaceuticals is a biotechnology business based in the US. Eyepoint Pharmaceuticals shares (EYPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.33 – a decrease of 1.48% over the previous week. Eyepoint Pharmaceuticals employs 121 staff and has a trailing 12-month revenue of around $45.7 million.

Our top picks for where to buy Eyepoint Pharmaceuticals stock

Buy Eyepoint Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Eyepoint Pharmaceuticals stock price (NASDAQ: EYPT)

Use our graph to track the performance of EYPT stocks over time.

Eyepoint Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$7.33
52-week range	$7.04 - $30.99
50-day moving average more info button	$9.77
200-day moving average more info button	$11.90
Wall St. target price	$33.45
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.99

Is it a good time to buy Eyepoint Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Eyepoint Pharmaceuticals price performance over time

Historical closes compared with the close of $7.25 from 2024-12-23

1 week (2024-12-18)	-2.55%
1 month (2024-11-26)	-19.44%
3 months (2024-09-25)	-11.04%
6 months (2024-06-25)	-12.23%

1 year (2023-12-22)	-67.89%
2 years (2022-12-23)	150.87%
3 years (2021-12-23)	13.55
5 years (2019-12-24)	15.2

Eyepoint Pharmaceuticals financials

Revenue TTM	$45.7 million
Gross profit TTM	$26.9 million
Return on assets TTM	-31.39%
Return on equity TTM	-74.68%
Profit margin	-226.57%
Book value	$4.09
Market Capitalization more info button	$507.8 million

TTM: trailing 12 months

Eyepoint Pharmaceuticals share dividends

We're not expecting Eyepoint Pharmaceuticals to pay a dividend over the next 12 months.

Have Eyepoint Pharmaceuticals's shares ever split?

Eyepoint Pharmaceuticals's shares were split on a 1:10 basis on 8 December 2020 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Eyepoint Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Eyepoint Pharmaceuticals shares which in turn could have impacted Eyepoint Pharmaceuticals's share price.

Eyepoint Pharmaceuticals share price volatility

Over the last 12 months, Eyepoint Pharmaceuticals's shares have ranged in value from as little as $7.04 up to $30.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eyepoint Pharmaceuticals's is 1.517. This would suggest that Eyepoint Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Eyepoint Pharmaceuticals overview

EyePoint Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc.

Frequently asked questions

null
What percentage of Eyepoint Pharmaceuticals is owned by insiders or institutions?
Currently 1.141% of Eyepoint Pharmaceuticals shares are held by insiders and 93.542% by institutions. How many people work for Eyepoint Pharmaceuticals?
Latest data suggests 121 work at Eyepoint Pharmaceuticals. When does the fiscal year end for Eyepoint Pharmaceuticals?
Eyepoint Pharmaceuticals's fiscal year ends in December. Where is Eyepoint Pharmaceuticals based?
Eyepoint Pharmaceuticals's address is: 480 Pleasant Street, Watertown, MA, United States, 02472 What is Eyepoint Pharmaceuticals's ISIN number?
Eyepoint Pharmaceuticals's international securities identification number is: US30233G2093 What is Eyepoint Pharmaceuticals's CUSIP number?
Eyepoint Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 74439M107